News & Updates

Show Multimedia Only

Nintedanib falls short in bladder cancer trial

21 Jun 2022 by

In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).

21 Jun 2022

IBD tied to slightly impaired fertility in men

18 Jun 2022

Men with inflammatory bowel disease (IBD) have a slightly reduced fertility, and this is observed in both ulcerative colitis and Crohn’s disease, as reported in a study.

18 Jun 2022

Original New Drug Application Approvals by US FDA (01 - 15 June 2022)

15 Jun 2022

New drug applications approved by US FDA as of 01 - 15 June 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

15 Jun 2022

HoLEP, RASP deliver equally excellent postoperative outcomes in benign prostatic hyperplasia

12 Jun 2022

The use of holmium laser enucleation of the prostate (HoLEP) and robotic-assisted simple prostatectomy (RASP) deliver comparable and good postoperative outcomes in patients with large benign prostatic hyperplasia (BPH), a new study has found.

12 Jun 2022

Frail women at risk of complications, repeat procedure after sling surgery

07 Jun 2022

Frailty is associated with a higher relative risk of 30-day complications, 1-year mortality, and repeat procedures for persistent incontinence or obstructed voiding at 1 year after sling surgery in older adults, suggests a recent study.

07 Jun 2022

Polycythemia ups risk of MACE, VTE in men on testosterone therapy

06 Jun 2022

Men receiving testosterone therapy (TT) who develop polycythemia are at greater risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in the first year of therapy, according to a recent study.

06 Jun 2022

Whole pelvic radiation therapy improves survival in high-risk prostate cancer

02 Jun 2022

Prostate cancer (PCa) patients with higher lymph node (LN) risk scores and Gleason grade who are treated with whole pelvis radiotherapy (WPRT) have better overall survival (OS), reports a study.

02 Jun 2022

Testosterone level does not predict postprostatectomy genomic risk score

01 Jun 2022

No clinical association exists between predefined genomic risk score and testosterone level in men undergoing radical prostatectomy, according to a study.

01 Jun 2022

Incontinence training with urotherapy helps children with cerebral palsy

31 May 2022

In the treatment of urinary incontinence, urotherapy appears to be effective in children with cerebral palsy, helping reduce symptoms although at a slower rate compared with their typically developing counterparts, according to a study.

31 May 2022

Chemoradiotherapy improves disease control in muscle-invasive bladder cancer

28 May 2022

Chemotherapy with 5-fluorouracil (5FU) and mitomycin C (MMC), when combined with radiotherapy, leads to better locoregional control over a 10-year window in patients with muscle-invasive bladder cancer (MIBC), a recent study has found.